Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.

Autor:	Aldrich SL; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Poweleit EA; Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Prows CA; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.; Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Martin LJ; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Strawn JR; Anxiety Disorders Research Program, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, United States.; Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Ramsey LB; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.; Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2019 Feb 19; Vol. 10, pp. 99. Date of Electronic Publication: 2019 Feb 19 (Print Publication: 2019).
DOI:	10.3389/fphar.2019.00099
Abstrakt:	In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders. However, pharmacogenetic studies examining CYP2C19 metabolizer status and es/citalopram treatment outcomes have largely focused on adults. We report a retrospective study of electronic medical record data from 263 youth < 19 years of age with anxiety and/or depressive disorders prescribed escitalopram or citalopram who underwent routine clinical CYP2C19 genotyping. Slower CYP2C19 metabolizers experienced more untoward effects than faster metabolizers ( p = 0.015), including activation symptoms ( p = 0.029) and had more rapid weight gain ( p = 0.018). A larger proportion of slower metabolizers discontinued treatment with es/citalopram than normal metabolizers ( p = 0.007). Meanwhile, faster metabolizers responded more quickly to es/citalopram ( p = 0.005) and trended toward less time spent in subsequent hospitalizations ( p = 0.06). These results highlight a disparity in treatment outcomes with es/citalopram treatment in youth with anxiety and/or depressive disorders when standardized dosing strategies were used without consideration of CYP2C19 metabolizer status. Larger, prospective trials are warranted to assess whether tailored dosing of es/citalopram based on CYP2C19 metabolizer status improves treatment outcomes in this patient population.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu